Have a feature idea you'd love to see implemented?
Let us know!
APLS Apellis Pharmaceuticals Inc
Price (delayed)
$27.58
Market cap
$3.36B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.73
Enterprise value
$3.47B
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims
Highlights
The EPS has surged by 53% year-on-year and by 21% since the previous quarter
APLS's net income is up by 49% year-on-year and by 20% since the previous quarter
The company's quick ratio rose by 43% QoQ but it fell by 6% YoY
The equity has declined by 23% year-on-year
The company's gross margin fell by 2.8% YoY
Key stats
What are the main financial stats of APLS
Market
Valuations
Earnings
Shares outstanding
121.77M
Market cap
$3.36B
Enterprise value
$3.47B
Price to earnings (P/E)
N/A
Price to book (P/B)
12.66
Price to sales (P/S)
5.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.52
Revenue
$628.79M
EBIT
-$299.92M
EBITDA
-$298.13M
Free cash flow
-$408.71M
Per share
Balance sheet
Liquidity
EPS
-$2.73
Free cash flow per share
-$3.3
Book value per share
$2.18
Revenue per share
$5.07
TBVPS
$7.3
Total assets
$904.48M
Total liabilities
$640.16M
Debt
$474.51M
Equity
$264.33M
Working capital
$690.81M
Debt to equity
1.8
Current ratio
5.08
Quick ratio
3.94
Net debt/EBITDA
-0.38
Margins
Efficiency
Dividend
EBITDA margin
-47.4%
Gross margin
86.4%
Net margin
-52.9%
Operating margin
-49.8%
Return on assets
-39.8%
Return on equity
-139%
Return on invested capital
-65.4%
Return on capital employed
-40.8%
Return on sales
-47.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APLS stock price
How has the Apellis Pharmaceuticals stock price performed over time
Intraday
2.22%
1 week
-1.22%
1 month
-10.31%
1 year
-43.67%
YTD
-53.93%
QTD
-4.37%
Financial performance
How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$628.79M
Gross profit
$543.16M
Operating income
-$313.13M
Net income
-$332.89M
Gross margin
86.4%
Net margin
-52.9%
The company's net margin has surged by 85% YoY and by 34% QoQ
APLS's operating margin has surged by 85% year-on-year and by 35% since the previous quarter
APLS's net income is up by 49% year-on-year and by 20% since the previous quarter
APLS's operating income is up by 49% year-on-year and by 23% since the previous quarter
Growth
What is Apellis Pharmaceuticals's growth rate over time
Valuation
What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
12.66
P/S
5.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.52
The EPS has surged by 53% year-on-year and by 21% since the previous quarter
The P/B is 51% less than the 5-year quarterly average of 25.7 and 49% less than the last 4 quarters average of 25.0
The equity has declined by 23% year-on-year
The stock's price to sales (P/S) is 98% less than its 5-year quarterly average of 255.6 and 61% less than its last 4 quarters average of 14.0
APLS's revenue is up by 20% since the previous quarter
Efficiency
How efficient is Apellis Pharmaceuticals business performance
The return on sales has surged by 86% year-on-year and by 35% since the previous quarter
The company's return on invested capital has surged by 78% YoY and by 48% QoQ
APLS's ROA is up by 47% year-on-year and by 20% since the previous quarter
APLS's ROE is up by 35% YoY and by 14% QoQ
Dividends
What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APLS.
Financial health
How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 41% more than its total liabilities
The company's quick ratio rose by 43% QoQ but it fell by 6% YoY
The company's current ratio rose by 35% QoQ
The company's debt is 80% higher than its equity
The equity has declined by 23% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.